This case report describes a 10-year-old boy with congenital immunodeficiency who developed a rare lung tumor linked to the Epstein–Barr virus. The child received bronchoscopic interventions such as electrosnaring, forceps excision, laser therapy, high-frequency electrocautery, and cryotherapy, along with intravenous immunoglobulin therapy. Tumor cells showed diffuse positivity for Epstein–Barr virus and low Ki-67 levels between 5 and 8 percent. CD4+ T-cell counts remained persistently low throughout the case. No adverse events or discontinuations were reported in this single instance. The main concern is that tumor recurrence and progression may still occur despite these treatments. Because this is a single case report, the findings are limited and cannot be generalized to other patients. Clinicians should consider this rare tumor in pediatric patients with unexplained pulmonary nodules and underlying immunodeficiency. More research is needed to confirm the role of these therapies and to understand long-term outcomes for similar patients.
Review of IVIG and bronchoscopic interventions for pediatric EBV-SMT in immunodeficiencyA rare lung tumor in a boy with immune issues may need IVIG and bronchoscopic procedures
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This source is a case report review focusing on a single 10-year-old boy with congenital immunodeficiency and an Epstein–Barr virus-associated smooth muscle tumor of the lung. The setting was not reported. The patient underwent bronchoscopic interventions such as electrosnaring, forceps excision, laser therapy, high-frequency electrocautery, and cryotherapy, combined with intravenous immunoglobulin therapy. No comparator group was included in this narrative.
Pathological findings showed Ki-67 positivity between 5% and 8% and diffuse EBER positivity. CD4+ T-cell counts remained persistently low throughout the case. The review notes that tumor recurrence and progression may occur despite the administered treatments. No adverse events or discontinuations were reported in this single case.
The authors highlight that treatments may not prevent tumor recurrence and progression. Pulmonary EBV-SMT should be considered in pediatric patients with unexplained pulmonary nodules and underlying immunodeficiency. This case illustrates the complexity of managing rare tumors in immunocompromised children. Further research is needed to define optimal management strategies for this condition.